Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

suptavumab

- PMLiVE

Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA

Globally, around 150 to 200 out of every million people have myasthenia gravis

- PMLiVE

Regeneron agrees research collaboration with Parabilis Medicines

Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties

- PMLiVE

Study shows infants given RSV vaccination benefit beyond first RSV season

The RSV virus is highly contagious and can cause serious respiratory illness for infants

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

- PMLiVE

Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

The deal includes an early-stage combination vaccine candidate for RSV and hMPV

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

The vaccine is already approved in the US for use in adults aged 60 years and older

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

- PMLiVE

Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants

Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight

- PMLiVE

Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links